Genmab reported 1.61B in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Agios Pharmaceuticals AGIO:US $ 99.27M 2.91M
Amarin AMRN:US 122.94M 5.42M
Amgen AMGN:US $ 3.74B 804M
Artemis Alpha ATS:LN 872K 40K
AstraZeneca AZN:LN 10.51B 1.79B
Bayer BAYN:GR 10.43B 1.33B
Biomarin Pharmaceutical BMRN:US $ 382.03M 133.66M
Bluebird Bio BLUE:US $ 122.29M 14.98M
Exelixis EXEL:US $ 272.74M 61.76M
Fresenius Medical Care FME:GR 4.2B 2.83M
Galapagos GLPG:NA 165.17M 9.07M
Genmab GEN:DC 1.61B 205M
GlaxoSmithKline GSK:LN 6.98B 1.65B
GN Store Nord GN:DC 3.97B 395M
H. Lundbeck A/S LUN:DC 3.5B 550M
Hikma Pharmaceutical HIK:LN 1.08B 209M
Immunogen IMGN:US $ 60.93M 1.62M
Insmed INSM:US $ 142.94M 12.26M
Lonza Group LONN:SW 2.33B 108M
Merck MRK:GR 4.03B 149M
Novartis NOVN:VX 9.96B 998M
Regeneron Pharmaceuticals REGN:US $ 1706.6M 605.4M
Seattle Genetics SGEN:US $ 559.51M 42.41M
William Demant Holding WDH:DC 7.57B 195M